高级搜索
陈越, 郑军. 组织激肽释放酶家族与胰腺癌[J]. 肿瘤防治研究, 2020, 47(7): 558-561. DOI: 10.3971/j.issn.1000-8578.2020.20.0106
引用本文: 陈越, 郑军. 组织激肽释放酶家族与胰腺癌[J]. 肿瘤防治研究, 2020, 47(7): 558-561. DOI: 10.3971/j.issn.1000-8578.2020.20.0106
CHEN Yue, ZHENG Jun. Tissue Kallikrein Family and Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 558-561. DOI: 10.3971/j.issn.1000-8578.2020.20.0106
Citation: CHEN Yue, ZHENG Jun. Tissue Kallikrein Family and Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 558-561. DOI: 10.3971/j.issn.1000-8578.2020.20.0106

组织激肽释放酶家族与胰腺癌

Tissue Kallikrein Family and Pancreatic Cancer

  • 摘要: 胰腺癌是迄今为止人类实质脏器中恶性程度较高的肿瘤之一,起病隐匿,发展速度快,五年生存率极低。组织激肽释放酶家族中多名成员被报道与胰腺癌的发生发展有关,其可能作为胰腺癌的潜在治疗靶点,探讨该家族相关成员与胰腺癌的关系具有一定的临床意义。

     

    Abstract: Pancreatic cancer is one of the most malignant tumors in human parenchymal organs by far, with the characteristics of insidious onset, rapid development and extremely low five-year survival rate. Several members of the tissue kallikrein family have been reported to be related to the occurrence and development of pancreatic cancer; they may be potential therapeutic targets for pancreatic cancer. This article reviews the relation between tissue kallikrein family and pancreatic cancer.

     

/

返回文章
返回